CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Your pituitary gland does not release growth hormone in a steady stream. It fires it in sharp pulses, maybe a dozen times across a 24-hour period, with the biggest burst happening in deep sleep, and those pulses are what drive most of the downstream effects people are chasing when they start looking at peptides. Understanding that single fact is the foundation for every decision that follows.

Here is the full chain so you have the map. Your hypothalamus sends a signal called growth hormone releasing hormone, which is the upstream trigger that tells your pituitary to fire. Your pituitary responds by releasing a pulse of growth hormone into circulation. That growth hormone travels to your liver and other tissues and stimulates the production of something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is what actually drives most of the tissue-level effects like muscle protein synthesis, fat metabolism, and recovery. The system is self-regulating because when growth hormone rises, the hypothalamus also releases something called somatostatin, which is the brake, and somatostatin blunts the next pulse so the system resets and stays within a natural rhythm. That is the whole pathway. CJC-1295 sits at the very top of that chain, mimicking the hypothalamus signal.

The first question anyone buying CJC-1295 has to answer is whether to buy the version with DAC or without it. DAC stands for drug affinity complex, and what it does mechanically is bind the peptide to albumin, which is a protein that circulates in your blood, and that albumin binding extends the half-life from roughly 30 minutes up to about seven days. The appeal is obvious because injecting once or twice a week instead of three times a day sounds better on paper. But the reason that tradeoff matters is tied directly to how the pituitary is designed to respond.

The pituitary does not respond well to a flat, continuous signal. It responds to sharp rises and falls because the receptors for growth hormone releasing hormone are tuned to that pulsatile pattern, and a steady baseline of stimulation begins to lose its effect over time in a way that a pulsatile signal does not. With DAC, instead of mimicking a natural hypothalamic pulse, you are essentially telling the pituitary to stay activated around the clock, which produces a flat elevation rather than timed pulses. If the goal is flat, sustained growth hormone elevation, then exogenous growth hormone itself accomplishes that with decades of clinical trial data behind it and known dosing precision. The DAC version offers neither the pulsatile physiology you are trying to preserve nor the clinical data you would want. No-DAC is the only version that actually serves the purpose of a secretagogue.

The second decision involves how you buy it, specifically whether you get CJC and Ipamorelin in a blend or in separate vials. Blends are not inherently a problem, but the math requires attention. A common configuration is five milligrams of CJC combined with five milligrams of Ipamorelin reconstituted in two milliliters of bacteriostatic water. In that setup, pulling 10 units on an insulin syringe delivers 250 micrograms of each compound. The reason to keep this math explicit is that if you ever switch between blend concentrations or between a blend and separate vials, the dose you think you are drawing is not the dose you are actually drawing.

The third decision is cycling, and this one has a specific mechanism behind it that most people get wrong. The common explanation is that you need to cycle CJC-1295 and Ipamorelin together to prevent the system from adapting. That is partially right, but it is not the CJC side driving that concern. Ipamorelin works through something called the ghrelin receptor, which is also labeled GHSR1a, and that receptor is prone to desensitization through a process where prolonged activation causes the cell to pull the receptor off its surface, a mechanism mediated by something called beta-arrestin. Fewer receptors on the surface means the same dose of Ipamorelin produces a smaller signal over time.

The clinical relevance of that desensitization is meaningful. After roughly 12 to 16 weeks of continuous use, IGF-1 levels can fall 20 to 30 percent from their peak even when the dose has not changed, and that decline is the signal that the receptors have downregulated enough to blunt the response. A standard cycling protocol of three months on and one month off is designed to allow receptor expression to recover before beginning the next cycle.

The CJC side does not carry this problem. CJC-1295 works through growth hormone releasing hormone receptors, and the evidence on those receptors comes from the tesamorelin clinical trials, since tesamorelin is another GHRH analog with essentially the same mechanism of action at the receptor level. In the FDA clinical trials that formed the basis for tesamorelin's approval, participants were dosed continuously for 52 weeks and IGF-1 levels remained stable from week 26 all the way through week 52 with no evidence of receptor attenuation. The GHRH receptor simply does not desensitize the way the ghrelin receptor does. So when you are cycling CJC and Ipamorelin together, you are cycling for the Ipamorelin, and the CJC is just along for the ride on that schedule.

The fourth decision is about when to stop using secretagogues entirely and move to exogenous growth hormone. Secretagogues work within the constraints of your biology. They can optimize the signal your hypothalamus sends and sharpen the pulses your pituitary produces, but they cannot push your peak output above what your pituitary is physically capable of generating. If your goals require more growth hormone than your own system can produce at its ceiling, secretagogues will not close that gap no matter how well the protocol is designed.

What also makes the transition a clean either-or is the somatostatin feedback mechanism. After a single injection of exogenous growth hormone, the resulting rise in circulating growth hormone triggers a somatostatin response that inhibits the GHRH pathway by 86 percent. That means if someone is running CJC-1295 alongside exogenous growth hormone, the exogenous GH injection is effectively silencing the very pathway CJC-1295 depends on to function. The two do not stack. One cancels the other, which is why the decision is a transition rather than an addition.

The thing worth sitting with is that secretagogues are not a weaker version of growth hormone therapy. They are a different category entirely, one that works with the architecture of the system rather than replacing it. The value is not just in the IGF-1 number they produce but in how they produce it, through preserved pulsatility, intact feedback loops, and a pituitary that is still doing its own work. When that is enough to reach your goal, it is the more physiologically conservative path. When it is not enough, you already know exactly why and exactly what the next step is.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness